0 citations
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
Journal of Drugs in Dermatology2023Vol. 22(2), pp. 139–147
Citations Over TimeTop 10% of 2023 papers
Melinda Gooderham, Leon Kircik, Matthew Zirwas, Mark Lee, Steven Kempers, Zoé Kececioglu Draelos, Laura K. Ferris, Terry Jones, Étienne Saint‐Cyr Proulx, Robert Bissonnette, Neal Bhatia, Robert Koppel, Scott Guenthner, Kimmie Eads, Howard G. Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert Higham, Michael Droege, David R. Berk
Abstract
gov identifier NCT03916081 J Drugs Dermatol. 2023;22(2):139-147. doi:10.36849/JDD.7295.
Related Papers
- → Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults(2020)22 cited
- → Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis(2021)15 cited
- → P480 Correlations of itch with quality of life and signs of atopic dermatitis across dupilumab trials(2017)7 cited
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- → Comment on “Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry”(2021)1 cited